CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Phase 2
Philadelphia, Pennsylvania, United States and 33 other locations
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...
Phase 3
East Windsor, New Jersey, United States of America and 88 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Philadelphia, Pennsylvania, United States and 83 other locations
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...
Phase 2
Philadelphia, Pennsylvania, United States and 98 other locations
24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W f...
Phase 4
East Windsor, New Jersey, United States
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherap...
Phase 4
East Windsor, New Jersey, United States
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Philadelphia, Pennsylvania, United States and 540 other locations
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Phase 1
Philadelphia, Pennsylvania, United States and 15 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
Philadelphia, Pennsylvania, United States and 555 other locations
Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema...
Phase 3
Philadelphia, Pennsylvania, United States and 98 other locations
Clinical trials
Research sites
Resources
Legal